AirSculpt Technologies, Inc. (AIRS) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows a challenging macro environment with a decline in same-store revenue and cases, despite some cost reductions and improved cash flow. The Q&A section highlights consumer hesitancy, uncertainty in revenue guidance, and lack of clear data on new initiatives like skin tightening. The leverage ratio improvement is positive, but overall, weak financial performance and guidance uncertainty suggest a negative sentiment.
Key Financial Performance
Revenue $44 million, declining 13.7% from the second quarter of 2024. The decline was driven by lower case volume due to the challenging macro environment.
Same-store revenue Declined approximately 22% over the prior year quarter. The decline reflects the challenging market environment and softness in consumer spending.
Adjusted EBITDA $5.8 million for a margin of 13.3% versus $6.9 million or a margin of 13.5% in the second quarter of 2024. The decline was due to revenue declines, but there was a sequential improvement from Q1 2025 of $2 million, mainly reflecting the sequential increase in revenue and cost reduction plans.
Cases Declined 14.1% to 3,392. The decline was due to operating in a challenging market environment with softness in consumer spending.
Average revenue per case $12,975, approximately flat to the second quarter of 2024.
Cost of service Decreased $1.6 million compared to the prior year period. As a percentage of revenue, it increased to 39.1% versus 36.9%, primarily due to fixed cost components such as rent and nursing, which do not scale down completely with short-term revenue fluctuations.
Selling, general and administrative expenses Decreased $11.6 million in the quarter compared to the same period in fiscal 2024. This reflects reductions in equity-based compensation, restructuring costs, and advertising expense.
Customer acquisition cost (CAC) $2,905 per case compared to $3,325 in the prior year quarter. The decline was driven by marketing and sales efforts gaining traction.
Adjusted net income $1.2 million or income of $0.02 per diluted share.
Cash flow from operations $5 million compared to $3.4 million in the second quarter of fiscal 2024. The increase reflects improved operational efficiency.
Cash $8.2 million as of June 30, 2025.
Gross debt outstanding $58.8 million as of June 30, 2025. The company repaid $16 million of debt during the quarter, including $5 million on the revolver and a $10 million prepayment on long-term debt.
Leverage ratio 2.87x at June 30, 2025, down from 3.76x as of March 31, 2025. The improvement reflects debt repayment and improved financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Skin tightening procedure pilot: Launched in three centers during Q2, with plans to expand to additional centers in Q3. The procedure addresses skin laxity, particularly following the use of GLP-1s.
Lead generation and consultation volume: Achieved record lead growth and increased consultation volume through optimized marketing strategies, including search engine marketing, social media, and online video.
Cost reduction plan: Achieved $2 million improvement in adjusted EBITDA from Q1 2025, reflecting sequential revenue increase and cost savings.
Customer acquisition cost (CAC): Reduced CAC to $2,905 per case from $3,325 in the prior year quarter, marking the first quarter-over-quarter decline since going public.
Technology upgrades: Upgraded IT systems for efficient sales call routing and expanded Salesforce usage, leading to higher consultation volumes and smoother customer processes.
Marketing reallocation: Shifted marketing spend to proven strategies, improving lead generation and reducing customer acquisition costs.
Financing options: Expanded financing options across all centers, with 50% of patients using financing in Q2, up from 44% in Q1.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenue for the quarter declined by 13.7% compared to the prior year, driven by lower case volumes and a challenging macroeconomic environment. Same-store revenue declined approximately 22% year-over-year.
Consumer Spending Uncertainty: Softness in consumer spending and economic conditions have negatively impacted case volumes and revenue. The company has built conservatism into its guidance due to this uncertainty.
Debt Levels: Although the company has reduced its debt by $16 million, it still has $58.8 million in gross debt outstanding, which could pose financial risks if economic conditions worsen.
Cost Structure Challenges: Fixed costs such as rent and nursing do not scale down with short-term revenue fluctuations, leading to increased cost of service as a percentage of revenue.
Customer Acquisition Costs: While customer acquisition costs (CAC) have decreased, they remain a significant expense at $2,905 per case, which could impact profitability if not managed effectively.
Market Environment: The company is operating in a challenging market environment with weakening consumer sentiment and inflationary pressures, which could further impact demand for its services.
Strategic Execution Risks: New growth initiatives, such as the skin tightening procedure pilot, are in early stages and have not yet contributed to revenue growth, posing risks to achieving strategic objectives.
Leadership Transition: The planned retirement of the CFO and the ongoing search for a replacement could disrupt financial strategy and operational continuity during the transition period.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Fiscal 2025 Revenue Guidance: The company expects fiscal 2025 revenue to be in the range of $160 million to $170 million.
Fiscal 2025 Adjusted EBITDA Guidance: Adjusted EBITDA is projected to be between $16 million and $18 million.
Economic Conditions Assumptions: Guidance reflects current economic conditions with some conservatism due to consumer spending uncertainty but does not anticipate a downturn in the economy.
Financing Solutions Impact: The company expects to see positive impacts on conversion rates from expanded financing options in the back half of the year.
Skin Tightening Procedure Pilot: The pilot of the skin tightening procedure, launched in three centers in Q2, will be extended to additional centers in Q3, with potential for meaningful opportunity.
Customer Experience Enhancements: Initiatives to elevate customer experience are planned for the back half of 2025 and into 2026.
Technology Investments: Investments in technology, including expanded financing options, upgraded IT systems, and Salesforce utilization, are expected to improve operational efficiency and consultation volumes.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the drivers for the revenue and EBITDA guidance in the second half of the year?
A:The company sees uncertainty with the consumer but has record-high leads and growth in consultations. However, consumers are hesitant to spend. The company is focusing on building a solid foundation aligned with five key priorities, cost management, and reducing marketing spend to stabilize revenue and improve EBITDA margins.
Q:What is the status of the skin tightening offering and its impact on guidance?
A:The company started a pilot for skin tightening in Q2 at three locations, which has shown strong interest. However, there are no standalone skin tightening expectations in the guidance yet. The company plans to expand the pilot and analyze its impact on revenue in the coming quarters.
Q:How are the 2024 centers performing, and what is the expectation for same-store case growth in the second half?
A:The 2024 centers are performing in line with expectations but lower than historical levels due to consumer pressures. Modest improvement in same-store metrics is expected as these centers enter the same-store pool. Q3 is expected to show a decline, but Q4 should see significant improvement due to easier comps and the full contribution of new centers.
Q:What is the seasonality impact expected in Q3 and Q4, and how will cost initiatives affect cash flow?
A:Q3 is expected to be slightly softer, with improvement in Q4. Cost initiatives, including reductions in marketing and SG&A spend, are expected to save over $3 million for the year, with significant impacts in Q3 and Q4.
Q:What is the progress of the London facility?
A:The London facility had a slow start but outperformed the rest of the chain in comp sales in the last quarter. However, it remains cash flow negative. The company is focused on improving its results.
Q:What is the state of the market and consumer sentiment?
A:The company observed typical seasonal patterns but noted choppiness in consumer behavior, with hesitancy to make purchases due to macroeconomic conditions. Leads and consultations are strong, and the company believes its initiatives and balance sheet position it better than independent plastic surgeons.
Q:What needs to happen before the company considers expansion opportunities?
A:The company is focused on improving same-center sales growth and achieving stability in its balance sheet. Once these are achieved, it will revisit expansion opportunities, as it sees significant white space in the U.S. market.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the results of the skin tightening pilot, stating it was too early to report. They also did not provide clear metrics or data on the performance of the London facility beyond general trends.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AirSculpt case
AirSculpt culture
AirSculpt today
BTIG LLC
CEO Director
Conference Instructions
Difficulty team
Director Raskin
Division Conference
Division Sam
GLPs customer
ICR Inc
ICR today
Inc Conference
Inc Greetings
Instructions conference
LLC Research
LLC Taylor
Malkin partner
Officer CEO
Officer Chief
Officer search
Partners LLC
Research Division
Research LLC
Salesforce consultation
Sam Shimon
Shimon Eiber
Taylor McCarthy
Technical Difficulty
acquisition signal
appointment concert
benefit action
consultation volume
engine
financing option
offering
use
AIRS Transcript
AirSculpt Technologies, Inc. (AIRS) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call highlights positive debt reduction and a strengthened balance sheet, but flat revenue growth and increased customer acquisition costs are concerns. The guidance for revenue and EBITDA shows modest growth expectations, and the Q&A indicates reliance on marketing strategies for improvement. The absence of new center openings and uncertainties in refinancing and macroeconomic conditions add risks. These mixed signals suggest a neutral stock price movement over the next two weeks.
AirSculpt Technologies, Inc. (AIRS) Q4 2025 Earnings Call Transcript
Unknown4-2
The earnings call reveals significant challenges: a 15% revenue decline, financial control issues, and a high debt level. Although there is some margin expansion and positive signs in body sculpting trends, the overall financial health is concerning. The Q&A section suggests cautious optimism for future revenue but lacks strong positive catalysts. Given these factors, the stock is likely to experience a negative reaction in the short term.
AirSculpt Technologies, Inc. (AIRS) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a negative outlook, with reduced revenue guidance, declining financial performance, and high leverage limiting flexibility. Despite some cost-cutting measures, the revenue and EBITDA have decreased, and the company faces challenges with new services. The Q&A highlighted uncertainties in cost savings and service expansion, with management providing vague responses. Given these factors, a negative stock price movement is likely, reflecting the company's current financial struggles and market uncertainties.
AirSculpt Technologies, Inc. (AIRS) Q2 2025 Earnings Call Transcript
Unknown8-1
The earnings call summary shows a challenging macro environment with a decline in same-store revenue and cases, despite some cost reductions and improved cash flow. The Q&A section highlights consumer hesitancy, uncertainty in revenue guidance, and lack of clear data on new initiatives like skin tightening. The leverage ratio improvement is positive, but overall, weak financial performance and guidance uncertainty suggest a negative sentiment.
AIRS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
